This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Confirming post #59 from a second method, which matters more than confirming it from a second person.
I would call the community position on SURMOUNT-4 and continuation versus withdrawal likely rather than established, and I would be comfortable defending that hedge.
That is a fair summary of where the discussion has got to.
What I can speak to on SURMOUNT-4 and continuation versus withdrawal is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.
The baseline characteristics table is the single most useful page for the questions that get asked here, because it tells you who the result applies to.
Nothing above should be read as advice about what anyone else should do.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field — setting out what I have, and where I think it stops being reliable. Collecting what is known about SURMOUNT-OSA in one place,…
|
+108 | 122 | 52k | 7d |
|
Journal club: indirect comparison between two programmes, defended and attacked — one year on
Posting this under the heading it deserves: Journal club: indirect comparison between two programmes, defended and attacked — one year on Everything below is what sits behind that. Asking about indirect…
|
+45 | 50 | 3k | 9mo |
|
Journal club: STEP-HFpEF and symptom endpoints
Journal club: STEP-HFpEF and symptom endpoints — setting out what I have, and where I think it stops being reliable. The question about step-hfpef and symptom endpoints that I actually want answered is the…
|
+18 | 22 | 2.5k | 11mo |
|
Journal club: LEADER as the historical anchor
Journal club: LEADER as the historical anchor Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of LEADER is wrong? I ask because I have…
|
+103 | 110 | 8.1k | 2h |
|
Journal club: STEP 1 and the treatment-policy estimand — does this still hold?
Asking directly, because I could not find a straight answer: Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Working notes on STEP 1 rather than a conclusion. I would rather…
|
+70 | 76 | 4.8k | 15h |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: Journal club: LEADER as the historical anchor
Posting this under the heading it deserves: Second pass at: Journal club: LEADER as the historical anchor Everything below is what sits behind that. Two things I would like separated before anyone answers on…
|
+75 | 81 | 2k | 2y |
|
Coming back to: Reading a meta-analysis you disagree with, fairly
Reading a meta-analysis you disagree with, fairly Writing it up because I had to work it out twice and would rather nobody else did. Reading a meta-analysis — I have the observation and I do not trust my…
|
+30 | 34 | 9.3k | 17mo |
|
Journal club: SELECT, absolute risk, and how it was reported
Journal club: SELECT, absolute risk, and how it was reported Writing it up because I had to work it out twice and would rather nobody else did. A question about what the numbers mean rather than what they…
|
2 | 52k | 1mo | |
|
SURPASS-2 and the comparator dose question that will not go away — what changed since
Posting this under the heading it deserves: SURPASS-2 and the comparator dose question that will not go away — what changed since Everything below is what sits behind that. What changes if the standard…
|
+2 | 6 | 5.5k | 7h |
|
Cagrilintide molecular characteristics and analytical considerations
Cagrilintide molecular characteristics and analytical considerations — setting out what I have, and where I think it stops being reliable. A methods question rather than a substantive one, about cagrilintide…
|
4 | 41k | 12mo |